VERUCERFONT
Verucerfont is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target CRHR1-IT1-CRHR1 protein.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 1 | — | — | — | 3 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | — | — | 2 |
| Traumatic stress disorders | D040921 | — | — | — | 2 | — | — | — | 2 |
| Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 3 | — | — | — | — | 3 |
| Social phobia | D000072861 | EFO_1001917 | F40.1 | 1 | — | — | — | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | 1 | — | — | — | — | 1 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | 1 | — | — | — | — | 1 |
| Adrenogenital syndrome | D047808 | — | E25.9 | 1 | — | — | — | — | 1 |
| Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VERUCERFONT |
| INN | verucerfont |
| Description | Verucerfont (GSK-561,679) is a drug developed by GlaxoSmithKline which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress, and activates the two corticotropin-releasing hormone receptors CRH-1 and CRH-2. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.
|
| Classification | Small molecule |
| Drug class | CRF-1 (corticotropin releasing factor) receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1 |
Identifiers
| PDB | — |
| CAS-ID | 885220-61-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1287935 |
| ChEBI ID | — |
| PubChem CID | 11596613 |
| DrugBank | — |
| UNII ID | X60608B091 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
LINC02210-CRHR1
LINC02210-CRHR1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 166 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use